Daily Endocrinology Research Analysis
Analyzed 29 papers and selected 3 impactful papers.
Summary
Top endocrine-metabolic advances today highlight immunometabolic regulation in adipose tissue, liver-specific insulin sensitivity as a determinant of prediabetes remission, and an adipocyte protein (ANKRD53) that couples lipolysis to mitochondrial oxidation. These studies jointly point to therapeutic strategies beyond weight loss, targeting immune-adipocyte crosstalk and hepatic insulin action.
Research Themes
- Adipose immunometabolism and aging-related insulin resistance
- Hepatic insulin sensitivity as a driver of prediabetes remission
- Coordination of lipolysis and mitochondrial β-oxidation in adipocytes
Selected Articles
1. Interleukin-10 expressing B lineage cells in visceral adipose tissue protect against aging-related insulin resistance and extend lifespan.
The study identifies IL-10–producing B lineage (B-10) cells as an expanded, dominant IL-10 source in aged visceral adipose tissue. Genetic and tissue-targeted perturbations show that BAFF-driven expansion of B-10 cells preserves barrier/anti-inflammatory tone, mitigates aging-related insulin resistance, and extends lifespan in mice.
Impact: This work uncovers a previously unappreciated immunoregulatory axis (BAFF–B-10–IL-10) within adipose tissue that causally links aging, inflammation, insulin resistance, and lifespan. It provides a mechanistic foundation for immunomodulatory strategies to treat metabolic aging.
Clinical Implications: Although preclinical, targeting BAFF or augmenting IL-10–producing B cells may represent strategies to improve insulin sensitivity in older adults with metabolic syndrome. Biomarker development around adipose BAFF/B-10 signatures could help stratify patients for immunometabolic therapies.
Key Findings
- IL-10–producing B-10 cells are markedly expanded in aged visceral adipose tissue in humans and mice and constitute the primary IL-10 source.
- B cell–specific IL-10 knockout exacerbates aging-related inflammation and insulin resistance and shortens lifespan; adoptive B-10 transfer partially rescues these phenotypes.
- Aged VAT increases BAFF levels, driving B-10 proliferation; VAT-specific BAFF overexpression expands B-10 cells, improves inflammation and insulin resistance, and prolongs lifespan, while BAFF knockdown blunts B-10 expansion.
Methodological Strengths
- Multi-system mechanistic evidence integrating human tissue profiling with mouse genetic models and adoptive cell transfer.
- Causal interrogation of the BAFF–B-10–IL-10 axis using tissue-specific overexpression/knockdown and phenotypic readouts (IR, inflammation, lifespan).
Limitations
- Translational relevance requires human interventional validation; most causal data are from murine models.
- The durability and safety of BAFF modulation or B-10 augmentation were not evaluated in humans.
Future Directions: Test BAFF inhibitors/agonists or B-10–based cellular therapies for metabolic endpoints in early-phase human trials; develop non-invasive biomarkers of adipose immunoregulatory tone.
Visceral adipose tissue (VAT) inflammation is considered as an important contributor of aging, however, whether there is endogenous factor(s) in VAT that counteract this process remains obscure. Here we reported that interleukin (IL)-10 expressing B lineage (B-10) cells are greatly expanded in aged VAT in human and mouse. In aged VAT, B-10 cells are the primary source of IL-10. B cell-specific knockout of IL-10 exaggerated aging-related inflammation and insulin resistance (IR) and reduced lifespan, which could be partially
2. Enduring improvements in hepatic insulin sensitivity predict sustained remission of prediabetes during a 3-year lifestyle intervention: results from the PREVIEW multinational diabetes prevention trial.
In a post-hoc analysis of the 3-year PREVIEW RCT, only 12% achieved sustained prediabetes remission. Maintainers exhibited greater weight and fat mass loss, but crucially showed persistent improvements in hepatic insulin sensitivity independent of weight change, distinguishing them from relapsers.
Impact: The study reframes diabetes prevention by highlighting hepatic insulin sensitivity—beyond weight loss—as a key predictor and potential target for sustaining remission of prediabetes.
Clinical Implications: Lifestyle and pharmacologic interventions should explicitly target hepatic insulin sensitivity (e.g., dietary composition, time-restricted eating, liver-targeted agents) to prevent relapse after initial improvement.
Key Findings
- Only 12% of high-risk adults maintained prediabetes remission over 3 years of lifestyle intervention.
- Maintainers achieved greater weight and fat mass loss than non-responders, yet sustained improvements in hepatic insulin sensitivity occurred independent of weight change.
- Relapsers progressively reverted to insulin resistance at years 2–3 compared with maintainers, despite similar changes in visceral adiposity index.
Methodological Strengths
- Large, multinational, multicenter RCT platform with 3-year follow-up and standardized protocols.
- Comparative trajectory analysis among maintainers, relapsers, and non-responders controlling for baseline covariates.
Limitations
- Post-hoc analysis limits causal inference; hepatic insulin sensitivity was inferred from surrogate markers rather than gold-standard clamps.
- Findings may not generalize beyond participants who completed the full protocol and assessments.
Future Directions: Prospective trials to test liver-targeted dietary patterns and pharmacotherapies (e.g., pioglitazone, GLP-1/GCG agents with hepatic action) on sustaining remission; incorporate direct measures of hepatic insulin sensitivity.
BACKGROUND: Recent investigation advocates the use of prediabetes remission as a goal of diabetes prevention. We aimed to compare changes in metabolic markers in participants with and without sustained remission of prediabetes during a 3-year lifestyle intervention. METHODS: This post-hoc analysis used data from the PREVIEW trial, a 3-year, multinational, multicenter, randomized controlled trial aiming to examine the effects of lifestyle interventions on prevention of type 2 diabetes among high-risk adults. Adult participants with prediabetes and overweight/obesity underwent 8-weeks of
3. ANKRD53 is downregulated in human obesity and coordinates lipolysis with mitochondrial oxidative metabolism in adipocytes.
ANKRD53, a human-specific adipocyte protein, is markedly reduced in obesity and inversely correlates with insulin resistance and triglycerides. Functionally, ANKRD53 enhances lipolysis and mitochondrial respiration in human adipocytes and channels fatty acids into β-oxidation via interaction with ACSL1; adipose-targeted overexpression in mice increases in vivo lipolysis.
Impact: This work identifies ANKRD53 as a previously unrecognized coordinator of lipolysis and oxidative metabolism, providing a concrete adipocyte-intrinsic target to improve metabolic efficiency in obesity.
Clinical Implications: Therapies that restore ANKRD53 function or its ACSL1-dependent routing of fatty acids may enhance metabolic flexibility and reduce lipid spillover in obesity-related insulin resistance.
Key Findings
- ANKRD53 expression in both SAT and VAT is reduced in obesity and inversely correlates with adiposity, insulin resistance indices, and triglycerides, while positively with adiponectin and HDL.
- ANKRD53 overexpression in human primary adipocytes enhances forskolin-stimulated lipolysis and mitochondrial respiration; silencing impairs these processes.
- ANKRD53 interacts with ACSL1, promotes its mitochondrial localization, and channels lipolysis-derived fatty acids into β-oxidation; ACSL1 knockdown abrogates ANKRD53 effects.
Methodological Strengths
- Human cohort transcriptomics (n=236) linked to metabolic phenotypes plus mechanistic validation in primary human adipocytes.
- Protein–protein interaction mapping and in vivo adipose-targeted overexpression confirming physiological relevance.
Limitations
- Causality in humans remains to be demonstrated; therapeutic modulation of ANKRD53 was not tested clinically.
- Mouse adipose overexpression was localized (iWAT), which may not recapitulate visceral depot physiology.
Future Directions: Develop small molecules or gene therapies to enhance ANKRD53 function; test metabolic outcomes and safety in preclinical models and early-phase human studies.
AIMS: Human adipose tissue is central to obesity-associated metabolic dysfunction. ANKRD53 is a human-specific, adipocyte-enriched ankyrin repeat scaffold protein with largely unknown function. We investigated its role in human adipocyte metabolism and the underlying mechanism. METHODS: RNA-seq analysis of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) from 236 individuals quantified ANKRD53 expression and its association with metabolic traits. In human primary adipocytes, we assessed lipolysis (free fatty acid and glycerol release) and mitochondrial respiration (oxygen consumption